Abstract
Thomas L Petty was the founder of modern long-term oxygen therapy (LTOT).1 In 1967, Petty's group published the seminal study of six patients with severe chronic airway obstruction, in whom LTOT improved clinical status, exercise capacity, secondary erythrocythemia, and pulmonary hypertension.2 Notably, all patients had severe hypoxaemia (partial pressure of oxygen [PaO2] 41·5–46·5 mm Hg) and four patients were severely hypercapnic (partial pressure of carbon dioxide [PaCO2] 55·0–61·5 mm Hg). Thereafter, two randomised controlled trials that were initiated in the 1970s established a clear survival benefit related to LTOT in patients with chronic obstructive pulmonary disease (COPD) with severe resting hypoxaemia: the Nocturnal Oxygen Therapy Trial (NOTT)3 and the British Medical Research Council (BMRC) trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
